On April 27, 2023 Veracyte, Inc. (Nasdaq: VCYT) reported that five abstracts providing new molecular insights into prostate and other cancers will be presented at the 2023 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, taking place in Chicago and online June 2-6 (Press release, Veracyte, APR 27, 2023, View Source [SID1234630628]). Three of the accepted abstracts leverage Veracyte’s Decipher GRID (Genomic Resource for Intelligent Discovery) database to explore potential opportunities for further personalizing treatment for patients with prostate cancer.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"At Veracyte, we are committed to partnering with the scientific community to uncover new insights that may ultimately help further transform cancer care for patients," said Marc Stapley, Veracyte’s chief executive officer. "We particularly look forward to study findings being presented at ASCO (Free ASCO Whitepaper) that leverage our Decipher GRID database to explore differences in how patients with prostate cancer might respond to particular treatments based on their genomic profiles, and that demonstrate our deep scientific capabilities in immuno-oncology."
The following abstracts will be presented at the 2023 ASCO (Free ASCO Whitepaper) Annual Meeting:
Title: Longitudinal transcriptome profiling of localized hormone-sensitive tumors in treatment-naïve ENACT patients with prostate cancer with and without enzalutamide (ENZA)
Presenter: Ashley Ross, M.D., Ph.D., Northwestern University Feinberg School of Medicine
Abstract #: 5026
Format: Poster
Date/Time: June 3, 2023, 8:00-11:00 a.m. CT
Location: McCormick Place, Hall A (Poster #120)
Title: Basal-luminal subtyping of localized high-risk prostate cancer and benefit of adding docetaxel to definitive radiotherapy with androgen suppression in the NRG Oncology/RTOG 0521 phase III trial
Presenter: Ryan Phillips, M.D., Ph.D., Mayo Clinic
Abstract #: 5094
Format: Poster
Date/Time: June 3, 2023, 8:00-11:00 a.m. CT
Location: McCormick Place, Hall A (Poster #188)
Title: Transcriptomic heterogeneity of metastatic disease timing within metastatic castration-sensitive prostate cancer
First Author: Philip Sutera, M.D., Johns Hopkins University
Abstract #: e17083
Format: Publication Only
Title: Biology and performance of pre- and post-pembrolizumab (Pembro) vesical imaging–reporting and data system (VI-RADS) to predict the pathological response in muscle-invasive urothelial bladder cancer (MIBC): Full data analysis from a clinical trials pipeline
Presenter: Andrea Necchi, M.D., Vita-Salute San Raffaele University
Abstract #: 4591
Format: Poster
Date/Time: June 3, 2023, 8:00-11:00 a.m. CT
Location: McCormick Place, Hall A (Poster #83)
Title: FOLFOXIRI plus bevacizumab and atezolizumab as upfront treatment of unresectable metastatic colorectal cancer (mCRC): Updated and overall survival results of the phase II randomized AtezoTRIBE study.
Presenter: Carlotta Antoniotti, M.D., Ph.D., Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa & Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana
Abstract #: 3500
Format: Oral Presentation
Date/Time: June 4, 2023, 8:00 a.m. CT
Location: McCormick Place, Hall D2